Medicaid Preferred Drug List (PDL) Program: Pharmacy and Therapeutics Committee Meeting Monday February 9, 2004 9:00 a.m. DMAS Board Room DRAFT AGENDA

• Welcome and Introductions

Patrick W. Finnerty, Director

• Comments from the Secretary of Health and Human Resources

The Honorable Jane H. Woods, Secretary of Health and Human Resources

• Comments from the Chairperson

Randy Axelrod, M.D.

 Acceptance of Minutes from January 6, 2004 Meeting Randy Axelrod, M.D. Chairman, P&T Committee Members

• Discussion of PDL criteria for the April 2004 and Cox II criteria

Randy Axelrod, M.D.
P&T Committee Members

• Drug Class Discussions for July 2004:

Mark Szalwinski, R.Ph.

Narcotics: Long Acting

Vice Chairman, P&T Committee

Antihyperkinesis (Meds For ADD/ADHD) CNS Stimulants

P&T Committee Members

Macrolides - Adult (Antibiotics)

Macrolides - Pediatrics (Antibiotics)

2nd Generation Quinolones- Systemic (Antibiotics)

3rd Generation Quinolones- Systemic (Antibiotics) 2nd Generation Cephalosporins (Antibiotics)

2rd Generation Cephalosporins (Antibiotics) 3rd Generation Cephalosporins (Antibiotics)

• Confidential Meeting

Confidential Meeting for P&T Committee Members, DMAS, and FHSC

Pursuant to 42 U.S.C. § 1396r-8 to discuss

pricing information

• P&T Committee Discussion

Randy Axelrod, M.D. P&T Committee Members

• Open Issues

Randy Axelrod, M.D.

• Next Meeting - April 21, 2004

Randy Axelrod, M.D.

Oral presentations: The P&T Committee in conjunction with the Department will be allocating a limited number of slots for interested parties to present scientific and clinical information on the specific drug classes that are listed on the Agenda. <u>All presentations must be clinical in nature and based on scientific material</u>. No anecdotal accounts are to be given. Each speaker will be allocated to a 3 - 5 minutes time slot. The actual speakers and number of speakers will be decided by the Chairperson based on relevancy of the information and time limitations.

If you are interested in providing specific clinical drug information, please submit your written comments or an outline of discussion points, indicate your request to speak at the meeting and the name of the presenter. Please send information to pdlinput@dmas.state.va.us by COB Friday, January 30, 2004.

Written information/presentations: The P&T Committee will accept written comments for consideration. Please send information to pdlinput@dmas.state.va.us by COB Friday, January 30, 2004.